Jorge Nieva
@nievamd
Followers
433
Following
112
Media
11
Statuses
204
Oncologist, scientist, teacher & learner
Pasadena, CA
Joined May 2016
Happy to see this important work on real world data of uncommon EGFR mutations publically available.
link.springer.com
Oncology and Therapy - Osimertinib is recommended, alongside afatinib, as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with atypical mutations in the epidermal...
0
0
0
🫁 As Lung Cancer Awareness Month continues, don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who reflects on the importance of #LCAM, the cultural shift he's seen around lung cancer, and why screening is critical. ➡️ Watch: https://t.co/pH4yA8p4LH
#lcsm
0
2
2
Advancing new drugs to patients is important. But equally important is ensuring that drug toxicity is minimized. Very proud to have been part of this important study.
jto.org
Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies...
0
0
1
My daughter has launched a sub stack project and is proving herself to be a terrific writer. I invite you all to read it and subscribe if you want to see more.
0
0
2
Very proud of Rahul Mudumba for completing this important pharmaco-economic analysis of ALK fusion lung cancer treatment.
jmcp.org
BACKGROUND: Alectinib, brigatinib, and lorlatinib are all preferred first-line (1L) therapies for anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in National Comprehens...
1
1
10
💊 How do steroids impact survival in patients undergoing immunotherapy for NSCLC? 🫁 Don't miss this insightful interview with @nievamd of @KeckMedicineUSC, who discusses recent bedside-to-bench research that addressed the question. ➡️ Watch: https://t.co/UERGUIbCtO
#lcsm
0
1
15
Diving beyond EGFR in NSCLC with an excellent session chaired by @SchenkLab, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from @christinemphmd @drgandara @mihaela_aldea @nievamd @riess_md
@OncLive #BTGLung2025 #LCSM #Oncology
0
3
20
A huge thanks to @nievamd, of @KECKSchool_USC, who stopped by during #BTGLung2025 to talk about the management of ALK rearrangements in NSCLC! Check out our site for exclusive insights from Dr Nieva and more! #lcsm #oncology
https://t.co/1a5dzPxT5l
0
2
8
‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 @sands_jacob @triparnasen @NarjustFlorezMD @DrEdKim @AnaVManana @OncLive
3
9
8
Join OncLive LIVE July 23, 3:30 PM PT. Engage w/ Narjust Florez, MD, Edward S. Kim, MD, Eric K. Singhi, MD & vote in interactive polls! See how your answers align w/ experts. Follow @OncLive & click 🔔 for alerts! #BTGLung2025 @lungoncdoc @DrEdKim @NarjustFlorezMD
0
8
13
The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, @StephenVLiu, @EnriquetaFelip & @nievamd discuss this approval & how to position taletrectinib among treatment options. 🎧 https://t.co/NmacJQBoIn
2
12
23
Tune in tomorrow for the latest episode of the @IASLC podcast, Lung Cancer Considered, where I discuss the recent FDA approval of taletrectinib in #ROS1 NSCLC, with Drs. @nievamd and @EnriquetaFelip. Where will this drug fit into the treatment landscape? Download tomorrow!
1
5
26
On July 17th, come to Pasadena to hear about lung cancer updates at our OncLive State of the Science Summit!
registration.onclive.com
OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the science driving...
1
2
9
A great conference for all who are interested in lung cancer. https://t.co/A7xoEQpHXA
0
0
4